バーキットリンパ腫治療薬の世界市場レポート 2025年

バーキットリンパ腫治療薬市場規模は、今後数年で力強い成長が見込まれます。2029年にはCAGR7.5％で16億6,000万米ドルに成長します。予測期間における成長の原動力は、個別化医療の進展、免疫療法の採用拡大、希少がんに関する研究の高まり、MYC阻害剤の開発、早期発見のための診断ツールの改善、臨床試験の増加、リンパ腫治療用バイオシミラーの出現、リンパ腫治療に対する認識と教育の向上です。主な動向としては、CAR-T細胞療法の進展、MYC標的療法の開発、リキッドバイオプシー応用の拡大、創薬における人工知能の統合、個別化治療のための精密医療、ドラッグデリバリーにおけるナノテクノロジーの利用拡大、診断におけるデジタル病理学の応用、モノクローナル抗体療法の進歩、AIによる治療反応予測などが挙げられます。

ヒト免疫不全ウイルス（HIV）の罹患率の上昇は、バーキットリンパ腫治療薬市場の拡大を促進すると予想されます。HIVは、免疫防御に不可欠なCD4+T細胞を攻撃することで免疫系を弱体化させるウイルスです。HIV感染者の増加は、無防備な性行為、認識不足、限られた医療アクセス、薬物使用者の間での注射針の共有、早期診断と治療を妨げる社会的偏見などの要因によるものです。HIVに感染すると免疫力が低下するため、エイズ関連リンパ腫に分類されるバーキットリンパ腫など、さまざまながんのリスクが高まる。この関連から、免疫不全患者のバーキットリンパ腫を管理・治療するための効果的な治療薬の需要が高まっています。例えば、2024年10月、英国保健保障庁は、2023年にイングランドで新たにHIV感染者と診断されたのは6,008人で、2022年の3,975人から51％増加したと報告しました。その結果、HIV罹患率の増加がバーキットリンパ腫治療薬市場を前進させています。

個別化医療に対する需要の高まりも、バーキットリンパ腫治療の進歩を後押ししています。個別化医療とは、治療効果を高めるために、遺伝的、環境的、生活習慣的要因に基づいて個々の患者に合わせた治療を行うことです。この傾向に拍車をかけているのは、ゲノミクスの革新、バイオマーカーに基づく診断法の利用可能性の増加、データ解析の強化、標的治療のニーズの高まりです。個別化医療は、遺伝子および分子プロファイルに基づく精密治療を可能にすることによってバーキットリンパ腫治療を改善し、有効性の向上、副作用の減少、患者の転帰の最適化をもたらします。例えば、2024年2月、個別化医療連合（PMC）は、FDAが合計26の個別化治療のうち、2023年に7つの新しい個別化がん治療を承認し、2022年の12の承認から増加したと報告しました。このように、個別化医療が重視されるようになったことで、バーキットリンパ腫治療薬の進歩が加速しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界バーキットリンパ腫治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のバーキットリンパ腫治療薬市場：成長率分析
• 世界のバーキットリンパ腫治療薬市場の実績：規模と成長, 2019-2024
• 世界のバーキットリンパ腫治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界バーキットリンパ腫治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバーキットリンパ腫治療薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• 標的療法
• 放射線治療
• 外科的介入
• 世界のバーキットリンパ腫治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• オーラル
• 皮下
• 筋肉内
• 世界のバーキットリンパ腫治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院の設定
• 専門クリニック
• 外来センター
• 在宅ヘルスケア
• 世界のバーキットリンパ腫治療薬市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 導入化学療法
• 地固め化学療法
• 高用量化学療法
• 世界のバーキットリンパ腫治療薬市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• CAR-T細胞療法
• 免疫チェックポイント阻害剤
• 世界のバーキットリンパ腫治療薬市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブルトン型チロシンキナーゼ阻害剤（BTK阻害剤）
• PI3K阻害剤
• BCL-2阻害剤
• 世界のバーキットリンパ腫治療薬市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線療法
• 強度変調放射線治療（IMRT）
• 定位放射線手術
• 世界のバーキットリンパ腫治療薬市場、外科的介入の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リンパ節切除
• 腫瘍切除

第7章 地域別・国別分析

• 世界のバーキットリンパ腫治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバーキットリンパ腫治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バーキットリンパ腫治療薬市場：競合情勢
• バーキットリンパ腫治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb
• AstraZeneca plc
• Novartis AG
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Baxter International Inc.
• Fresenius Kabi USA LLC
• Incyte Corporation
• Kyowa Kirin Co. Ltd.
• Seagen Inc.
• Karyopharm Therapeutics Inc.
• Adienne Pharma & Biotech SA
• Spectrum Pharmaceuticals Inc.
• Rhizen Pharmaceuticals S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バーキットリンパ腫治療薬市場2029：新たな機会を提供する国
• バーキットリンパ腫治療薬市場2029：新たな機会を提供するセグメント
• バーキットリンパ腫治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Burkitt lymphoma therapeutics encompass a range of medical treatments designed to manage and cure Burkitt lymphoma, a highly aggressive and rapidly progressing form of non-Hodgkin lymphoma that originates in B cells. These treatments aim to eliminate cancer cells, reduce the risk of relapse, and enhance overall survival rates through intensive and customized therapeutic protocols. The selection of therapeutics for Burkitt lymphoma is based on specific disease characteristics, including the variant type, the patient's overall health, and the response to treatment.

The primary treatment modalities for Burkitt lymphoma therapeutics include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgical intervention. Chemotherapy serves as the main treatment approach, utilizing potent anti-cancer drugs to target and destroy rapidly dividing lymphoma cells. These drugs can be administered through various routes, such as intravenous, oral, subcutaneous, and intramuscular. Additionally, treatment is delivered across multiple healthcare settings, including hospitals, specialty clinics, outpatient centers, and home healthcare environments.

The burkitt lymphoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides burkitt lymphoma therapeutics market statistics, including burkitt lymphoma therapeutics industry global market size, regional shares, competitors with a burkitt lymphoma therapeutics market share, detailed burkitt lymphoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the burkitt lymphoma therapeutics industry. This burkitt lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The burkitt lymphoma therapeutics market size has grown strongly in recent years. It will grow from $1.15 billion in 2024 to $1.24 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to the rising prevalence of Burkitt lymphoma, advancements in monoclonal antibodies, expansion of immunotherapy applications, increased awareness of non-Hodgkin lymphoma, the emergence of targeted therapies, enhanced funding for cancer research, the adoption of precision medicine, and collaborations between pharmaceutical companies and research institutions.

The burkitt lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $1.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The projected growth in the forecast period is driven by advancements in personalized medicine, increasing adoption of immunotherapies, rising research on rare cancers, development of MYC inhibitors, improved diagnostic tools for early detection, a growing number of clinical trials, emergence of biosimilars for lymphoma treatments, and increased awareness and education on lymphoma therapies. Major trends include progress in CAR-T cell therapy, development of MYC-targeted therapies, expansion of liquid biopsy applications, integration of artificial intelligence in drug discovery, precision medicine for personalized treatments, increased use of nanotechnology in drug delivery, application of digital pathology in diagnosis, advancements in monoclonal antibody therapies, and AI-driven treatment response prediction.

The rising incidence of human immunodeficiency virus (HIV) is expected to drive the expansion of the Burkitt lymphoma therapeutics market. HIV is a virus that weakens the immune system by attacking CD4+ T cells, which are essential for immune defense. The increase in HIV cases is due to factors such as unprotected sexual practices, lack of awareness, limited healthcare access, needle sharing among drug users, and social stigma preventing early diagnosis and treatment. As HIV infection weakens the immune system, it raises the risk of various cancers, including Burkitt lymphoma, which is classified as an AIDS-related lymphoma. This connection increases the demand for effective therapeutics to manage and treat Burkitt lymphoma in immunocompromised patients. For example, in October 2024, the UK Health Security Agency reported 6,008 new HIV diagnoses in England in 2023, a 51% rise from 3,975 cases in 2022. As a result, the increasing incidence of HIV is driving the Burkitt lymphoma therapeutics market forward.

The growing demand for personalized medicine is also propelling the advancement of Burkitt lymphoma treatments. Personalized medicine involves tailoring therapies to individual patients based on their genetic, environmental, and lifestyle factors to enhance treatment effectiveness. This trend is fueled by innovations in genomics, the increasing availability of biomarker-based diagnostics, enhanced data analytics, and the growing need for targeted therapies. Personalized medicine improves Burkitt lymphoma treatment by enabling precision therapies based on genetic and molecular profiles, resulting in increased efficacy, fewer side effects, and optimized patient outcomes. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved seven new personalized cancer treatments in 2023, out of a total of 26 personalized therapies, up from 12 approvals in 2022. The growing emphasis on personalized medicine is thus accelerating advancements in Burkitt lymphoma therapeutics.

Leading companies in the Burkitt lymphoma therapeutics market are prioritizing clinical research to refine treatment strategies, enhance efficacy, and address relapsed or refractory cases. Clinical trials for Burkitt lymphoma investigate new therapies, drug combinations, and treatment approaches to assess their safety, effectiveness, and potential side effects. For instance, in May 2022, Wuhan Bio-Raid Biotechnology Co. Ltd., in collaboration with Huazhong University of Science and Technology, conducted a study to evaluate the clinical efficacy and toxicity of CD19/CD22 CAR T-cell immunotherapy alone and in combination with autologous stem cell transplantation (ASCT) in adult patients with relapsed and refractory Burkitt lymphoma. After a median follow-up of 12.5 months, results indicated that CD19/CD22 CAR T-cell therapy combined with ASCT was effective for certain adults with relapsed or refractory Burkitt lymphoma. These findings highlight the potential of innovative immunotherapies in improving patient outcomes.

Major players in the burkitt lymphoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Fresenius Kabi USA LLC, Incyte Corporation, Kyowa Kirin Co. Ltd., Seagen Inc., Karyopharm Therapeutics Inc., Adienne Pharma & Biotech SA, Spectrum Pharmaceuticals Inc., Rhizen Pharmaceuticals S.A., Verastem Inc., TG Therapeutics Inc.

North America was the largest region in the burkitt lymphoma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in burkitt lymphoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the burkitt lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The burkitt lymphoma therapeutics market consists of revenues earned by entities by providing services such as treatment administration, patient monitoring, central nervous system (CNS) prophylaxis, stem cell transplantation, clinical trial services, diagnostic testing, disease management programs and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The burkitt lymphoma therapeutics market also includes sales of monoclonal antibodies, chemotherapeutic agents, tyrosine kinase inhibitors, and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Burkitt Lymphoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on burkitt lymphoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for burkitt lymphoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The burkitt lymphoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy; Surgical Intervention
• 2) By Route Of Administration: Intravenous; Oral; Subcutaneous; Intramuscular
• 3) By End-User: Hospital Settings; Specialty Clinics; Outpatient Centers; Home Healthcare
• Subsegments:
• 1) By Chemotherapy: Induction Chemotherapy; Consolidation Chemotherapy; High-Dose Chemotherapy
• 2) By Immunotherapy: Monoclonal Antibodies; CAR-T Cell Therapy; Immune Checkpoint Inhibitors
• 3) By Targeted Therapy: Bruton's Tyrosine Kinase Inhibitors (BTK Inhibitors); PI3K Inhibitors; BCL-2 Inhibitors
• 4) By Radiation Therapy: External Beam Radiation Therapy; Intensity-Modulated Radiation Therapy (IMRT); Stereotactic Radiosurgery
• 5) By Surgical Intervention: Lymph Node Excision; Tumor Resection
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Burkitt Lymphoma Therapeutics Market Characteristics

3. Burkitt Lymphoma Therapeutics Market Trends And Strategies

4. Burkitt Lymphoma Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Burkitt Lymphoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Burkitt Lymphoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Burkitt Lymphoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Burkitt Lymphoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Burkitt Lymphoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Burkitt Lymphoma Therapeutics Total Addressable Market (TAM)

6. Burkitt Lymphoma Therapeutics Market Segmentation

• 6.1. Global Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgical Intervention
• 6.2. Global Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Oral
• Subcutaneous
• Intramuscular
• 6.3. Global Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Settings
• Specialty Clinics
• Outpatient Centers
• Home Healthcare
• 6.4. Global Burkitt Lymphoma Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Induction Chemotherapy
• Consolidation Chemotherapy
• High-Dose Chemotherapy
• 6.5. Global Burkitt Lymphoma Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• CAR-T Cell Therapy
• Immune Checkpoint Inhibitors
• 6.6. Global Burkitt Lymphoma Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bruton's Tyrosine Kinase Inhibitors (BTK Inhibitors)
• PI3K Inhibitors
• BCL-2 Inhibitors
• 6.7. Global Burkitt Lymphoma Therapeutics Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Intensity-Modulated Radiation Therapy (IMRT)
• Stereotactic Radiosurgery
• 6.8. Global Burkitt Lymphoma Therapeutics Market, Sub-Segmentation Of Surgical Intervention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lymph Node Excision
• Tumor Resection

7. Burkitt Lymphoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Burkitt Lymphoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Burkitt Lymphoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Burkitt Lymphoma Therapeutics Market

• 8.1. Asia-Pacific Burkitt Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Burkitt Lymphoma Therapeutics Market

• 9.1. China Burkitt Lymphoma Therapeutics Market Overview
• 9.2. China Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Burkitt Lymphoma Therapeutics Market

• 10.1. India Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Burkitt Lymphoma Therapeutics Market

• 11.1. Japan Burkitt Lymphoma Therapeutics Market Overview
• 11.2. Japan Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Burkitt Lymphoma Therapeutics Market

• 12.1. Australia Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Burkitt Lymphoma Therapeutics Market

• 13.1. Indonesia Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Burkitt Lymphoma Therapeutics Market

• 14.1. South Korea Burkitt Lymphoma Therapeutics Market Overview
• 14.2. South Korea Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Burkitt Lymphoma Therapeutics Market

• 15.1. Western Europe Burkitt Lymphoma Therapeutics Market Overview
• 15.2. Western Europe Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Burkitt Lymphoma Therapeutics Market

• 16.1. UK Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Burkitt Lymphoma Therapeutics Market

• 17.1. Germany Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Burkitt Lymphoma Therapeutics Market

• 18.1. France Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Burkitt Lymphoma Therapeutics Market

• 19.1. Italy Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Burkitt Lymphoma Therapeutics Market

• 20.1. Spain Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Burkitt Lymphoma Therapeutics Market

• 21.1. Eastern Europe Burkitt Lymphoma Therapeutics Market Overview
• 21.2. Eastern Europe Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Burkitt Lymphoma Therapeutics Market

• 22.1. Russia Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Burkitt Lymphoma Therapeutics Market

• 23.1. North America Burkitt Lymphoma Therapeutics Market Overview
• 23.2. North America Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Burkitt Lymphoma Therapeutics Market

• 24.1. USA Burkitt Lymphoma Therapeutics Market Overview
• 24.2. USA Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Burkitt Lymphoma Therapeutics Market

• 25.1. Canada Burkitt Lymphoma Therapeutics Market Overview
• 25.2. Canada Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Burkitt Lymphoma Therapeutics Market

• 26.1. South America Burkitt Lymphoma Therapeutics Market Overview
• 26.2. South America Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Burkitt Lymphoma Therapeutics Market

• 27.1. Brazil Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Burkitt Lymphoma Therapeutics Market

• 28.1. Middle East Burkitt Lymphoma Therapeutics Market Overview
• 28.2. Middle East Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Burkitt Lymphoma Therapeutics Market

• 29.1. Africa Burkitt Lymphoma Therapeutics Market Overview
• 29.2. Africa Burkitt Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Burkitt Lymphoma Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Burkitt Lymphoma Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Burkitt Lymphoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Burkitt Lymphoma Therapeutics Market Competitive Landscape
• 30.2. Burkitt Lymphoma Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Burkitt Lymphoma Therapeutics Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. Gilead Sciences Inc.
• 31.5. Amgen Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Baxter International Inc.
• 31.8. Fresenius Kabi USA LLC
• 31.9. Incyte Corporation
• 31.10. Kyowa Kirin Co. Ltd.
• 31.11. Seagen Inc.
• 31.12. Karyopharm Therapeutics Inc.
• 31.13. Adienne Pharma & Biotech SA
• 31.14. Spectrum Pharmaceuticals Inc.
• 31.15. Rhizen Pharmaceuticals S.A.

32. Global Burkitt Lymphoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Burkitt Lymphoma Therapeutics Market

34. Recent Developments In The Burkitt Lymphoma Therapeutics Market

35. Burkitt Lymphoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Burkitt Lymphoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Burkitt Lymphoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Burkitt Lymphoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer